Clinical Trial Sponsors: King Abdullah International Medical Research Center

  Source:		NCT02190799

    		Anti-MERS-CoV Convalescent Plasma Therapy

			First Update June 12, 2014
			Last Update November 19, 2018

			Brief Summary
			Since the first report of the Middle East Respiratory Syndrome
			Corona virus (MERS- CoV) in September 2012,
			more than 800 cases have been reported to
			the World Health Organization (WHO) with
			substantial mortality.

			Detailed Description
			World knowledge about this virus is accumulating
			but data about the clinical presentations of
			infected patients and common treatments,
			including ribavirin, interferon and methylprednisolone,
			lack evidence. Although drugs with anti-
			coronavirus (CoV) activities have been identified,
			as yet no anti- MERs- CoV drug has been
			approved and a vaccine has yet to be developed.
			Previous reports on other viral infections including
			SARS have suggested that convalescent
			plasma or serum is effective where no other
			treatment is available or in an emergency. A
			recently completed systematic review and
			meta-analysis by the University of Nottingham
			- World Health Organization Collaborating
			Center indicates that convalescent plasma
			therapy may be the most promising near-term
			therapy patients with for MERS- CoV infection.
			In this study, investigators will study the
			pharmacokinetics of immunoglobulin in response
			to convalescent plasma administration in order
			to inform a much larger study which will
			investigate the efficacy of convalescent plasma.
			Plasma will be collected from patients who
			recently recovered from MERS-CoV, Health
			Care Workers who had potential exposure and
			are tested for anti MERS-CoV serology and
			RT-PCR after obtaining their consent. This
			convalescent plasma will be stored in the blood
			bank as per their policies and procedures.
			Patients with MERS-CoV positive after meeting
			the eligibility criteria will receive 2 units of
			convalescent plasma . Clinical data as well as
			the standard laboratory studies will be collected
			at baseline, 30 mins after first dose, 30 mins
			after second dose, day 1, 3, 7, 14, 28 of hospital
			stay after enrollment.

     		                         Embed       Tweet       Print